{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T18:27:48Z","timestamp":1795026468314,"version":"4.10.2"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006447","name":"University of Zurich","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006447","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n                <jats:title>Abstract<\/jats:title>\n                <jats:p>The therapeutic response of patients with psoriatic arthritis (PsA) varies greatly and is often unsatisfactory. Accordingly, it is essential to individualise treatment selection to minimise long-term complications. This study aimed to identify factors that might predict treatment response to biological and targeted synthetic disease-modifying antirheumatic drugs (bDMARDs and tsDMARDs) in patients with PsA and to outline their potential application using artificial intelligence (AI). Five electronic databases were screened to identify relevant studies. A random-effects meta-analysis was performed for factors that were investigated in at least four studies. Finally, 37 studies with a total of 17,042 patients were included. The most frequently investigated predictors in these studies were sex, age, C-reactive protein (CRP), the Health Assessment Questionnaire (HAQ), BMI, and disease duration. The meta-analysis revealed that male sex (odds ratio (OR)\u2009=\u20092.188, 95% confidence interval (CI)\u2009=\u20091.912\u20132.503) and higher baseline CRP (1.537, 1.111\u20132.125) were associated with greater treatment response. Older age (0.982, 0.975\u20130.99), higher baseline HAQ score (0.483, 0.336\u20130.696), higher baseline DAPSA score (0.789, 0.663\u20130.938), and higher baseline tender joint count (TJC) (0.97, 0.945\u20130.996) were negatively correlated with the response to therapy. The other factors were not statistically significant but might be of clinical importance in the context of a complex AI test battery. Further studies are needed to validate these findings and identify novel factors that could guide personalised treatment decisions for PsA patients, in particular in developing AI applications. In accordance with the latest medical developments, decision-support tools based on supervised learning algorithms have been proposed as a clinical application of these predictors.\n<jats:table-wrap><jats:table><jats:tbody>\n                      <jats:tr>\n                        <jats:td align=\"left\"><jats:bold>Key messages<\/jats:bold><\/jats:td>\n                      <\/jats:tr>\n                      <jats:tr>\n                        <jats:td align=\"left\">\u2022 <jats:italic>Given the often unsatisfactory and unpredictable therapeutic response in patients with Psoriatic Arthritis (PsA), treatment selection must be highly individualized.<\/jats:italic>\u2022 <jats:italic>A systematic literature review was conducted to identify the most reliable predictors of treatment response to biologic and targeted synthetic disease-modifying antirheumatic drugs in PsA patients.<\/jats:italic>\u2022 <jats:italic>The potential integration of these predictors into AI tools for routine clinical practice is discussed.<\/jats:italic><\/jats:td>\n                      <\/jats:tr>\n                    <\/jats:tbody><\/jats:table><\/jats:table-wrap><\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10067-024-07193-y","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T17:02:53Z","timestamp":1730134973000},"page":"3723-3746","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Factors predicting treatment response to biological and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis \u2013 a systematic review and meta-analysis"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-8738-8918","authenticated-orcid":false,"given":"Tabea","family":"K\u00fcnzler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Bamert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3417-7210","authenticated-orcid":false,"given":"Haiko","family":"Sprott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,28]]},"reference":[{"key":"7193_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/2475530318812244","volume":"4","author":"JA Singh","year":"2018","unstructured":"Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A et al (2018) 2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. J Psoriasis Psoriatic Arthritis 4:31\u201358. https:\/\/doi.org\/10.1177\/2475530318812244","journal-title":"J Psoriasis Psoriatic Arthritis"},{"key":"7193_CR2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.7861\/clinmedicine.17-1-65","volume":"17","author":"LC Coates","year":"2017","unstructured":"Coates LC, Helliwell PS (2017) Psoriatic arthritis: state of the art review. CME Rheumatol 17:65\u201370. https:\/\/doi.org\/10.7861\/clinmedicine.17-1-65","journal-title":"CME Rheumatol"},{"key":"7193_CR3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/art.1780070113","volume":"7","author":"BS Blumberg","year":"1964","unstructured":"Blumberg BS, Bunim JJ, Calmns E, Meyer A (1964) ARA nomenclature and classification of arthritis and rheumatism (Tentative). Arthritis Rheumatol 7:93\u201397. https:\/\/doi.org\/10.1002\/art.1780070113","journal-title":"Arthritis Rheumatol"},{"key":"7193_CR4","doi-asserted-by":"publisher","first-page":"ii14","DOI":"10.1136\/ard.2004.032482","volume":"64","author":"DD Gladman","year":"2005","unstructured":"Gladman DD, Antoni C, Mease P, Clegg DO, Nash P (2005) Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64:ii14-7. https:\/\/doi.org\/10.1136\/ard.2004.032482","journal-title":"Ann Rheum Dis"},{"key":"7193_CR5","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0049-0172(73)90035-8","volume":"3","author":"JMH Moll","year":"1973","unstructured":"Moll JMH, Wright V (1973) Psoriatic arthritis. Semin Arthritis Rheum 3:55\u201378. https:\/\/doi.org\/10.1016\/0049-0172(73)90035-8","journal-title":"Semin Arthritis Rheum"},{"key":"7193_CR6","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.clinthera.2023.01.006","volume":"45","author":"A Panagiotopoulos","year":"2023","unstructured":"Panagiotopoulos A, Fragoulis GE (2023) Comorbidities in psoriatic arthritis: a narrative review. Clin Ther 45:177\u2013189. https:\/\/doi.org\/10.1016\/j.clinthera.2023.01.006","journal-title":"Clin Ther"},{"key":"7193_CR7","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.jaad.2020.10.031","volume":"84","author":"K Colaco","year":"2021","unstructured":"Colaco K, Widdifield J, Luo J, Rosen CF, Alhusayen R, Paterson JM et al (2021) Trends in mortality and cause-specific mortality among patients with psoriasis and psoriatic arthritis in Ontario, Canada. J Am Acad Dermatol 84:1302\u20131309. https:\/\/doi.org\/10.1016\/j.jaad.2020.10.031","journal-title":"J Am Acad Dermatol"},{"key":"7193_CR8","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","volume":"391","author":"DJ Veale","year":"2018","unstructured":"Veale DJ, Fearon U (2018) The pathogenesis of psoriatic arthritis. Lancet 391:2273\u20132284. https:\/\/doi.org\/10.1016\/S0140-6736(18)30830-4","journal-title":"Lancet"},{"key":"7193_CR9","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","volume":"41","author":"A Ogdie","year":"2015","unstructured":"Ogdie A, Weiss P (2015) The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am 41:545\u2013568. https:\/\/doi.org\/10.1016\/j.rdc.2015.07.001","journal-title":"Rheum Dis Clin North Am"},{"issue":"Suppl 1","key":"7193_CR10","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1002\/msc.1692","volume":"20","author":"S Hackett","year":"2022","unstructured":"Hackett S, Coates LC (2022) Outcome measures in psoriatic arthritis: Where next? Musculoskelet Care 20(Suppl 1):S22\u2013S31. https:\/\/doi.org\/10.1002\/msc.1692","journal-title":"Musculoskelet Care"},{"key":"7193_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/03009742.2023.2247703","volume":"53","author":"K Losinska","year":"2023","unstructured":"Losinska K, Michelsen B, Kavanaugh A, Korkosz M, Haugeberg G (2023) Psoriatic arthritis: improvement in outcomes but persistent sex difference - 5-year follow-up study of a Norwegian outpatient clinic population. Scand J Rheumatol 53:1\u201311. https:\/\/doi.org\/10.1080\/03009742.2023.2247703","journal-title":"Scand J Rheumatol"},{"key":"7193_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1759720X20962623","volume":"12","author":"M Noviani","year":"2020","unstructured":"Noviani M, Feletar M, Nash P, Leung YY (2020) Choosing the right treatment for patients with psoriatic arthritis. Ther Adv Musculoskelet Dis 12:1\u201317. https:\/\/doi.org\/10.1177\/1759720X20962623","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"7193_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clim.2019.108318","volume":"211","author":"J Pouw","year":"2020","unstructured":"Pouw J, Leijten E, Radstake T, Boes M (2020) Emerging molecular biomarkers for predicting therapy response in psoriatic arthritis: a review of literature. Clin Immunol 211:1\u20138. https:\/\/doi.org\/10.1016\/j.clim.2019.108318","journal-title":"Clin Immunol"},{"key":"7193_CR14","doi-asserted-by":"publisher","first-page":"150","DOI":"10.31138\/mjr.33.1.150","volume":"33","author":"CG Gialouri","year":"2022","unstructured":"Gialouri CG, Evangelatos G, Fragoulis GE (2022) Choosing the appropriate target for the treatment of psoriatic arthritis: TNF\u03b1, IL-17, IL-23 or JAK Inhibitors? Mediterr J Rheumatol 33:150\u201361. https:\/\/doi.org\/10.31138\/mjr.33.1.150","journal-title":"Mediterr J Rheumatol"},{"key":"7193_CR15","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3899\/jrheum.220315","volume":"50","author":"YY Leung","year":"2023","unstructured":"Leung YY, Korotaeva TV, Candia L, Pedersen SJ, Bautista Molano W, Ruderman EM et al (2023) Management of peripheral arthritis in patients with psoriatic arthritis: an updated literature review informing the 2021 GRAPPA treatment recommendations. J Rheumatol 50:119\u2013130. https:\/\/doi.org\/10.3899\/jrheum.220315","journal-title":"J Rheumatol"},{"issue":"700","key":"7193_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/annrheumdis-2020-217159","volume":"79","author":"L Gossec","year":"2020","unstructured":"Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M et al (2020) EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 79(700):1\u201312. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217159","journal-title":"Ann Rheum Dis"},{"key":"7193_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lanepe.2023.100706","volume":"33","author":"B Michelsen","year":"2023","unstructured":"Michelsen B, Ostergaard M, Nissen MJ, Ciurea A, Moller B, Ornbjerg LM et al (2023) Differences and similarities between the EULAR\/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe. Lancet Reg 33:1\u201312. https:\/\/doi.org\/10.1016\/j.lanepe.2023.100706","journal-title":"Lancet Reg"},{"key":"7193_CR18","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1136\/annrheumdis-2021-220097","volume":"80","author":"U Lindstrom","year":"2021","unstructured":"Lindstrom U, Di Giuseppe D, Delcoigne B, Glintborg B, Moller B, Ciurea A et al (2021) Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration. Ann Rheum Dis 80:1410\u20131418. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220097","journal-title":"Ann Rheum Dis"},{"key":"7193_CR19","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00296-019-04416-3","volume":"40","author":"EG Favalli","year":"2020","unstructured":"Favalli EG, Becciolini A, Carletto A, Conti F, Amato G, Fusaro E et al (2020) Efficacy and retention rate of adalimumab in rheumatoid arthritis and psoriatic arthritis patients after first-line etanercept failure: the FEARLESS cohort. Rheumatol Int 40:263\u2013272. https:\/\/doi.org\/10.1007\/s00296-019-04416-3","journal-title":"Rheumatol Int"},{"key":"7193_CR20","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates LC, Soriano ER, Corp N, Bertheussen H, Callis Duffin K, Campanholo CB et al (2022) Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol 18:465\u2013479. https:\/\/doi.org\/10.1038\/s41584-022-00798-0","journal-title":"Nat Rev Rheumatol"},{"key":"7193_CR21","doi-asserted-by":"publisher","first-page":"386148","DOI":"10.1155\/2014\/386148","volume":"2014","author":"CI Daien","year":"2014","unstructured":"Daien CI, Morel J (2014) Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine. Mediators Inflamm 2014:386148. https:\/\/doi.org\/10.1155\/2014\/386148","journal-title":"Mediators Inflamm"},{"key":"7193_CR22","doi-asserted-by":"publisher","first-page":"924","DOI":"10.3390\/jpm12060924","volume":"12","author":"E Dorochow","year":"2022","unstructured":"Dorochow E, K\u00f6hm M, Hahnefeld L, Gurke R (2022) Metabolic profiling in rheumatoid arthritis, psoriatic arthritis, and psoriasis: elucidating pathogenesis, improving diagnosis, and monitoring disease activity. J Pers Med 12:924. https:\/\/doi.org\/10.3390\/jpm12060924","journal-title":"J Pers Med"},{"issue":"19\u201326","key":"7193_CR23","first-page":"31074721","volume":"38","author":"EG Favalli","year":"2020","unstructured":"Favalli EG, Conti F, Selmi C, Iannone F, Bucci R, D\u2019Onofrio F et al (2020) Retrospective evaluation of patient profiling and effectiveness of apremilast in an Italian multicentric cohort of psoriatic arthritis patients. Clin Exp Rheumatol 38(19\u201326):31074721","journal-title":"Clin Exp Rheumatol"},{"key":"7193_CR24","doi-asserted-by":"publisher","first-page":"708","DOI":"10.3904\/kjim.2018.349","volume":"34","author":"KJ Kim","year":"2019","unstructured":"Kim KJ, Tagkopoulos I (2019) Application of machine learning in rheumatic disease research. Korean J Intern Med 34:708\u2013722. https:\/\/doi.org\/10.3904\/kjim.2018.349","journal-title":"Korean J Intern Med"},{"key":"7193_CR25","doi-asserted-by":"publisher","first-page":"63","DOI":"10.37737\/ace.22009","volume":"4","author":"O Sachiko","year":"2022","unstructured":"Sachiko O, Tadahiro G (2022) Introduction to supervised machine learning in clinical epidemiology. Ann Clin Epidemiol 4:63\u201371. https:\/\/doi.org\/10.37737\/ace.22009","journal-title":"Ann Clin Epidemiol"},{"key":"7193_CR26","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.jad.2020.11.104","volume":"281","author":"L Squarcina","year":"2021","unstructured":"Squarcina L, Villa FM, Nobile M, Grisan E, Brambilla P (2021) Deep learning for the prediction of treatment response in depression. J Affect Disord 281:618\u2013622. https:\/\/doi.org\/10.1016\/j.jad.2020.11.104","journal-title":"J Affect Disord"},{"key":"7193_CR27","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1016\/j.csbj.2021.07.003","volume":"19","author":"R Rafique","year":"2021","unstructured":"Rafique R, Islam SMR, Kazi JU (2021) Machine learning in the prediction of cancer therapy. Comput Struct Biotechnol J 19:4003\u20134017. https:\/\/doi.org\/10.1016\/j.csbj.2021.07.003","journal-title":"Comput Struct Biotechnol J"},{"key":"7193_CR28","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"7193_CR29","volume-title":"EndNote. EndNote 20 ed","author":"TheEndNoteTeam","year":"2013","unstructured":"TheEndNoteTeam (2013) EndNote. EndNote 20 ed. Clarivate, Philadelphia"},{"key":"7193_CR30","unstructured":"MedicineMatters. At a glance: Common scores used in rheumatology 2018 [updated 21 June 2024; cited 20 December 2023]. Available from: https:\/\/rheumatology.medicinematters.com\/treatment\/patient-reported-outcomes-\/at-a-glance-rheumatology-scores\/16077860. Accessed 20 Dec 2023."},{"key":"7193_CR31","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3109\/03009742.2014.962081","volume":"44","author":"F Iannone","year":"2015","unstructured":"Iannone F, Lopriore S, Bucci R, Scioscia C, Anelli MG, Notarnicola A et al (2015) Two-year survival rates of anti-TNF-\u03b1 therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA. Scand J Rheumatol 44:192\u2013199. https:\/\/doi.org\/10.3109\/03009742.2014.962081","journal-title":"Scand J Rheumatol"},{"key":"7193_CR32","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/j.ajhg.2023.08.010","volume":"110","author":"C Zhang","year":"2023","unstructured":"Zhang C, Shestopaloff K, Hollis B, Kwok CH, Hon C, Hartmann N et al (2023) Response to anti-IL17 therapy in inflammatory disease is not strongly impacted by genetic background. Am J Hum Genet 110:1817\u20131824. https:\/\/doi.org\/10.1016\/j.ajhg.2023.08.010","journal-title":"Am J Hum Genet"},{"key":"7193_CR33","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1136\/annrheumdis-2012-202347","volume":"73","author":"KM Fagerli","year":"2014","unstructured":"Fagerli KM, Lie E, van der Heijde D, Heiberg MS, Lexberg AS, Rodevand E et al (2014) The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. Ann Rheum Dis 73:132\u2013137. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202347","journal-title":"Ann Rheum Dis"},{"key":"7193_CR34","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.3389\/fphar.2019.01497","volume":"10","author":"S D\u2019Angelo","year":"2019","unstructured":"D\u2019Angelo S, Cantini F, Ramonda R, Cantarini L, Carletto A, Chimenti MS et al (2019) Effectiveness of adalimumab for the treatment of psoriatic arthritis: an italian real-life retrospective study. Front Pharmacol 10:1497. https:\/\/doi.org\/10.3389\/fphar.2019.01497","journal-title":"Front Pharmacol"},{"key":"7193_CR35","doi-asserted-by":"publisher","first-page":"321","DOI":"10.5021\/ad.22.003","volume":"34","author":"S Oh","year":"2022","unstructured":"Oh S, Choi S, Yoon H-S (2022) Available alternative biologics and disease groups influence biologic drug survival in patients with psoriasis and psoriatic arthritis. Ann Dermatol 34:321\u2013330. https:\/\/doi.org\/10.5021\/ad.22.003","journal-title":"Ann Dermatol"},{"key":"7193_CR36","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1080\/09546634.2020.1854428","volume":"33","author":"G Chatzimichail","year":"2022","unstructured":"Chatzimichail G, G\u00fcnther J, St\u00e4nder S, Tha\u00e7i D (2022) Drug survival of secukinumab, ustekinumab, and certolizumab pegol in psoriasis: a 2-year, monocentric, retrospective study. J Dermatolog Treat 33:1749\u20131753. https:\/\/doi.org\/10.1080\/09546634.2020.1854428","journal-title":"J Dermatolog Treat"},{"key":"7193_CR37","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s40261-019-00782-9","volume":"39","author":"F Iannone","year":"2019","unstructured":"Iannone F, Semeraro A, Carlino G, Santo L, Bucci R, Quarta L et al (2019) Effectiveness of certolizumab-pegol in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis based on the biopure registry: can early response predict late outcomes? Clin Drug Investig 39:565\u2013575. https:\/\/doi.org\/10.1007\/s40261-019-00782-9","journal-title":"Clin Drug Investig"},{"key":"7193_CR38","doi-asserted-by":"publisher","unstructured":"Becciolini, A, Parisi, S, Caccavale, R, Bravi, E, Lumetti, F, Andracco, R, et al (2022) Adalimumab and ABP 501 in the treatment of a large cohort of patients with inflammatory arthritis: a real life retrospective analysis. J Pers Med 12. https:\/\/doi.org\/10.3390\/jpm12030335","DOI":"10.3390\/jpm12030335"},{"key":"7193_CR39","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1201\/9781003107347","volume-title":"Doing meta-analysis with R: a hands-on guide","author":"M Harrer","year":"2021","unstructured":"Harrer M, Cuijpers P, Furukawa TA, Ebert DD (2021) Doing meta-analysis with R: a hands-on guide, 1st edn. Chapman & Hall\/CRC Press, Boca Raton, FL and London, p 2021","edition":"1"},{"key":"7193_CR40","unstructured":"Ottawa Hospital Research Institute. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analysis 2021 [updated 3 May 2021; cited 17 December 2023]. Available from: https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed 17 Dec 2023"},{"key":"7193_CR41","unstructured":"Cochrane Editorial Board. Risk of Bias 2 (RoB 2) tool 2021 [updated May 2022; cited 17 December 2023]. Available from: https:\/\/methods.cochrane.org\/risk-bias-2. Accessed 17 Dec 2023"},{"key":"7193_CR42","unstructured":"Erasmus Universiteit Rotterdam (2023) Egger regression and Begg and Mazumdar correlation test [cited 17 December 2023]. Available from: https:\/\/www.erim.eur.nl\/research-support\/meta-essentials\/user-manual\/work-with-the-workbooks\/publication-bias-analysis-sheet\/egger-regression-and-begg-and-mazumdar-rank-correlation-test\/. Accessed 17 Dec 2023"},{"key":"7193_CR43","unstructured":"Reed Siemieniuk, GG (2017) What is GRADE? [updated 3 April 2023; cited 17 December 2023]. Available from: https:\/\/bestpractice.bmj.com\/info\/us\/toolkit\/learn-ebm\/what-is-grade\/. Accessed 17 Dec 2023"},{"key":"7193_CR44","first-page":"23","volume":"30","author":"MS Chimenti","year":"2012","unstructured":"Chimenti MS, Perricone C, Graceffa D, Di Muzio G, Ballanti E, Guarino MD et al (2012) Complement system in psoriatic arthritis: a useful marker in response prediction and monitoring of anti-TNF treatment. Clin Exp Rheumatol 30:23\u201330","journal-title":"Clin Exp Rheumatol"},{"key":"7193_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2022.917939","volume":"13","author":"V Venerito","year":"2022","unstructured":"Venerito V, Lopalco G, Abbruzzese A, Colella S, Morrone M, Tangaro S et al (2022) A machine learning approach to predict remission in patients with psoriatic arthritis on treatment with secukinumab. Front Immunol 13:1\u20138. https:\/\/doi.org\/10.3389\/fimmu.2022.917939","journal-title":"Front Immunol"},{"key":"7193_CR46","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1002\/acr.22257","volume":"66","author":"S-C Au","year":"2014","unstructured":"Au S-C, Ramirez-Fort MK, Gottlieb AB (2014) Analysis of trial data for infliximab and golimumab: baseline C-reactive protein level and prediction of therapeutic response in patients with psoriatic arthritis. Arthritis Care Res 66:1114\u20131118. https:\/\/doi.org\/10.1002\/acr.22257","journal-title":"Arthritis Care Res"},{"key":"7193_CR47","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1136\/annrheumdis-2014-205389","volume":"74","author":"P Hojgaard","year":"2015","unstructured":"Hojgaard P, Glintborg B, Hetland ML, Hansen TH, Lage-Hansen PR, Petersen MH et al (2015) Association between tobacco smoking and response to tumour necrosis factor \u03b1 inhibitor treatment in psoriatic arthritis: results from the DANBIO registry. Ann Rheum Dis 74:2130\u20132136. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205389","journal-title":"Ann Rheum Dis"},{"key":"7193_CR48","unstructured":"Sch\u00fcnemann HJ (2011) The GRADE approach [cited 27 December 2023]. Available from: https:\/\/handbook-5-1.cochrane.org\/chapter_12\/12_2_1_the_grade_approach.htm. Accessed 27 Dec 2023"},{"key":"7193_CR49","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3109\/03009742.2012.715186","volume":"42","author":"F Iannone","year":"2013","unstructured":"Iannone F, Fanizzi R, Scioscia C, Anelli MG, Lapadula G (2013) Body mass does not affect the remission of psoriatic arthritis patients on anti-TNF-alpha therapy. Scand J Rheumatol 42:41\u201344","journal-title":"Scand J Rheumatol"},{"key":"7193_CR50","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1002\/art.37876","volume":"65","author":"B Glintborg","year":"2013","unstructured":"Glintborg B, Ostergaard M, Krogh NS, Andersen MD, Tarp U, Loft AG et al (2013) Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor alpha inhibitor therapy: results from the Danish Nationwide DANBIO Registry. Arthritis Rheumatol 65:1213\u20131223","journal-title":"Arthritis Rheumatol"},{"key":"7193_CR51","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1159\/000522008","volume":"238","author":"A Ortolan","year":"2022","unstructured":"Ortolan A, Lorenzin M, Leo G, Pampaloni F, Messina F, Doria A et al (2022) Secukinumab drug survival in psoriasis and psoriatic arthritis patients: a 24-month real-life study. Dermatology (Basel, Switzerland) 238:897\u2013903. https:\/\/doi.org\/10.1159\/000522008","journal-title":"Dermatology (Basel, Switzerland)"},{"key":"7193_CR52","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1136\/annrheumdis-2016-210283","volume":"76","author":"B Michelsen","year":"2017","unstructured":"Michelsen B, Kristianslund EK, Hammer HB, Fagerli KM, Lie E, Wier\u00f8d A et al (2017) Discordance between tender and swollen joint count as well as patient's and evaluator's global assessment may reduce likelihood of remission in patients with rheumatoid arthritis and psoriatic arthritis: data from the prospective multicentre NORDMARD study. Ann Rheum Dis 76:708\u2013711","journal-title":"Ann Rheum Dis"},{"key":"7193_CR53","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1136\/annrheumdis-2017-211284","volume":"76","author":"B Michelsen","year":"2017","unstructured":"Michelsen B, Kristianslund EK, Sexton J, Hammer HB, Fagerli KM, Lie E et al (2017) Do depression and anxiety reduce the likelihood of remission in rheumatoid arthritis and psoriatic arthritis? Data from the prospective multicentre NOR-DMARD study. Ann Rheum Dis 76:1906\u20131910","journal-title":"Ann Rheum Dis"},{"key":"7193_CR54","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1093\/rheumatology\/key203","volume":"57","author":"F Behrens","year":"2018","unstructured":"Behrens F, Koehm M, Schwaneck EC, Schmalzing M, Gnann H, Greger G et al (2018) Minimal disease activity is a stable measure of therapeutic response in psoriatic arthritis patients receiving treatment with adalimumab. Rheumatology (Oxford) 57:1938\u20131946. https:\/\/doi.org\/10.1093\/rheumatology\/key203","journal-title":"Rheumatology (Oxford)"},{"key":"7193_CR55","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1136\/annrheumdis-2016-eular.1777","volume":"75","author":"P H\u00f8jgaard","year":"2016","unstructured":"H\u00f8jgaard P, Glintborg B, Kristensen LE, Love TJ, Gudbjornsson B, Dreyer L (2016) Obesity impairs the response to tumour necrosis factor-alpha inhibitors in psoriatic arthritis: Results from the DANBIO and ICEBIO registries. Ann Rheum Dis 75:340","journal-title":"Ann Rheum Dis"},{"key":"7193_CR56","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s00296-020-04564-x","volume":"40","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, McInnes IB, Strand V, FitzGerald O, Ahmad HA, Elbez Y et al (2020) Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritis. Rheumatol Int 40:1021\u20131028","journal-title":"Rheumatol Int"},{"key":"7193_CR57","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1136\/ard.2006.060079","volume":"66","author":"J Gratacos","year":"2007","unstructured":"Gratacos J, Casado E, Real J, Torre-Alonso JC (2007) Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate. Ann Rheum Dis 66:493\u2013497. https:\/\/doi.org\/10.1136\/ard.2006.060079","journal-title":"Ann Rheum Dis"},{"key":"7193_CR58","doi-asserted-by":"publisher","first-page":"568","DOI":"10.3899\/jrheum.110763","volume":"39","author":"S Iervolino","year":"2012","unstructured":"Iervolino S, Di Minno MND, Peluso R, Lofrano M, Russolillo A, Di Minno G et al (2012) Predictors of early minimal disease activity in patients with psoriatic arthritis treated with tumor necrosis factor-\u03b1 blockers. J Rheumatol 39:568\u2013573","journal-title":"J Rheumatol"},{"key":"7193_CR59","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3899\/jrheum.150744","volume":"43","author":"LE Kristensen","year":"2016","unstructured":"Kristensen LE, Lie E, Jacobsson LTH, Christensen R, Mease PJ, Bliddal H et al (2016) Effectiveness and feasibility associated with switching to a second or third TNF inhibitor in patients with psoriatic arthritis: a cohort study from southern Sweden. J Rheumatol 43:81\u201387","journal-title":"J Rheumatol"},{"key":"7193_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/rmdopen-2020-001519","volume":"7","author":"R Ramonda","year":"2021","unstructured":"Ramonda R, Lorenzin M, Carriero A, Chimenti MS, Scarpa R, Marchesoni A et al (2021) Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: A 24-month prospective, multicentre study. RMD Open 7:1\u201314","journal-title":"RMD Open"},{"key":"7193_CR61","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1136\/ard.2009.111856","volume":"69","author":"F Van den Bosch","year":"2010","unstructured":"Van den Bosch F, Manger B, Goupille P, McHugh N, Rodevand E, Holck P et al (2010) Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. Ann Rheum Dis 69:394\u2013399","journal-title":"Ann Rheum Dis"},{"key":"7193_CR62","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1136\/annrheumdis-2021-220263","volume":"80","author":"JS Smolen","year":"2021","unstructured":"Smolen JS, Siebert S, Korotaeva TV, Selmi C, Bergmans P, Gremese E et al (2021) Effectiveness of IL-12\/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results. Ann Rheum Dis 80:1419\u20131428","journal-title":"Ann Rheum Dis"},{"key":"7193_CR63","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1093\/rheumatology\/kep423","volume":"49","author":"AA Saad","year":"2010","unstructured":"Saad AA, Ashcroft DM, Watson KD, Symmons DPM, Noyce PR, Hyrich KL (2010) Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 49:697\u2013705","journal-title":"Rheumatology (Oxford)"},{"key":"7193_CR64","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1093\/rheumatology\/key140","volume":"57","author":"P Hojgaard","year":"2018","unstructured":"Hojgaard P, Ballegaard C, Cordtz R, Zobbe K, Clausen M, Glintborg B et al (2018) Gender differences in biologic treatment outcomes-a study of 1750 patients with psoriatic arthritis using Danish Health Care Registers. Rheumatology (Oxford) 57:1651\u20131660. https:\/\/doi.org\/10.1093\/rheumatology\/key140","journal-title":"Rheumatology (Oxford)"},{"key":"7193_CR65","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13075-022-02771-4","volume":"24","author":"I Miyagawa","year":"2022","unstructured":"Miyagawa I, Nakayamada S, Ueno M, Miyazaki Y, Iwata S, Kubo S et al (2022) Impact of serum interleukin-22 as a biomarker for the differential use of molecular targeted drugs in psoriatic arthritis: a retrospective study. Arthritis Res Ther 24:86","journal-title":"Arthritis Res Ther"},{"key":"7193_CR66","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s40744-023-00548-y","volume":"10","author":"A Ogdie","year":"2023","unstructured":"Ogdie A, Gladman DD, Coates LC, Pournara E, Parikh B, Mease PJ (2023) Inhibition of interleukin-17 in patients with oligoarticular psoriatic arthritis. Rheumatol Ther 10:849\u2013860","journal-title":"Rheumatol Ther"},{"key":"7193_CR67","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1136\/annrheumdis-2012-201697","volume":"72","author":"CL Wagner","year":"2013","unstructured":"Wagner CL, Visvanathan S, Elashoff M, McInnes IB, Mease PJ, Krueger GG et al (2013) Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab. Ann Rheum Dis 72:83\u201388","journal-title":"Ann Rheum Dis"},{"key":"7193_CR68","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/acr.22529","volume":"67","author":"A Haddad","year":"2015","unstructured":"Haddad A, Thavaneswaran A, Ruiz-Arruza I, Pellett F, Chandran V, Cook RJ et al (2015) Minimal disease activity and antitumor necrosis factor therapy in psoriatic arthritis. Arthritis Care Res 67:842\u2013847","journal-title":"Arthritis Care Res"},{"key":"7193_CR69","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1097\/RHU.0000000000000751","volume":"24","author":"R Queiro","year":"2018","unstructured":"Queiro R, Brandy A, Rosado MC, Lorenzo A, Coto P, Carriles C et al (2018) Minimal disease activity and patient- acceptable symptom state in psoriatic arthritis: a real-world evidence study with ustekinumab. J Clin Rheumatol 24:381\u2013384","journal-title":"J Clin Rheumatol"},{"key":"7193_CR70","doi-asserted-by":"publisher","first-page":"350","DOI":"10.3899\/jrheum.150805","volume":"43","author":"FM Perrotta","year":"2016","unstructured":"Perrotta FM, Marchesoni A, Lubrano E (2016) Minimal disease activity and remission in psoriatic arthritis patients treated with anti-TNF-a drugs. J Rheumatol 43:350\u2013355","journal-title":"J Rheumatol"},{"issue":"55\u201365","key":"7193_CR71","first-page":"27750274","volume":"42","author":"PD Carvalho","year":"2017","unstructured":"Carvalho PD, Duarte C, Vieira-Sousa E, Cunha-Miranda L, Avila-Ribeiro P, Santos H et al (2017) Predictors of response to TNF blockers in patients with polyarticular psoriatic arthritis. Acta Reumatol Port 42(55\u201365):27750274","journal-title":"Acta Reumatol Port"},{"key":"7193_CR72","doi-asserted-by":"publisher","first-page":"690","DOI":"10.3899\/jrheum.181272","volume":"47","author":"E Vieira-Sousa","year":"2020","unstructured":"Vieira-Sousa E, Eusebio M, Avila-Ribeiro P, Khmelinskii N, Cruz-Machado R, Rocha TM et al (2020) Real-world longterm effectiveness of tumor necrosis factor inhibitors in psoriatic arthritis patients from the rheumatic diseases portuguese register. J Rheumatol 47:690\u2013700","journal-title":"J Rheumatol"},{"key":"7193_CR73","doi-asserted-by":"publisher","first-page":"52","DOI":"10.4081\/reumatismo.2020.1266","volume":"72","author":"FM Perrotta","year":"2020","unstructured":"Perrotta FM, Delle Sedie A, Scriffignano S, Volpe P, Cordisco E, Milano N et al (2020) Remission, low disease activity and improvement of pain and function in psoriatic arthritis patients treated with il-12\/23 and il-17 inhibitors. A multicenter prospective study. Reumatismo 72:52\u201359","journal-title":"Reumatismo"},{"key":"7193_CR74","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s40744-022-00445-w","volume":"9","author":"L Eder","year":"2022","unstructured":"Eder L, Tony HP, Odhav S, Agirregoikoa EG, Korkosz M, Schwartzman S et al (2022) Responses to Ixekizumab in male and female patients with psoriatic arthritis: results from two randomized, phase 3 clinical trials. Rheumatol Ther 9:919\u2013933","journal-title":"Rheumatol Ther"},{"key":"7193_CR75","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/cei.13451","volume":"201","author":"V Venerito","year":"2020","unstructured":"Venerito V, Natuzzi D, Bizzoca R, Lacarpia N, Cacciapaglia F, Lopalco G et al (2020) Serum sCD40L levels are increased in patients with psoriatic arthritis and are associated with clinical response to apremilast. Clin Exp Immunol 201:200\u2013204","journal-title":"Clin Exp Immunol"},{"key":"7193_CR76","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","volume":"73","author":"A Kavanaugh","year":"2014","unstructured":"Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD et al (2014) Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis 73:1020\u20131026","journal-title":"Ann Rheum Dis"},{"key":"7193_CR77","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1002\/art.30117","volume":"63","author":"B Glintborg","year":"2011","unstructured":"Glintborg B, \u00c3stergaard M, Dreyer L, Krogh NS, Tarp U, Hansen MS et al (2011) Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with antitumor necrosis factor \u03b1 therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheumatol 63:382\u2013390","journal-title":"Arthritis Rheumatol"},{"key":"7193_CR78","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s13075-023-03182-9","volume":"25","author":"MM Luchetti Gentiloni","year":"2023","unstructured":"Luchetti Gentiloni MM, Paci V, Carletto A, Zabotti A, Ramonda R, Chimenti MS et al (2023) Upadacitinib effectiveness and factors associated with minimal disease activity achievement in patients with psoriatic arthritis: preliminary data of a real-life multicenter study. Arthritis Res Ther 25:196","journal-title":"Arthritis Res Ther"},{"key":"7193_CR79","doi-asserted-by":"crossref","unstructured":"AlAujan SS, Almalag HM, Assiri GA, Alodaibi FA, Omair MA (2023) Fibromyalgia rapid screening tool (FiRST): Arabic translation and cross-cultural adaptation and validation. Healthcare (Basel).:11","DOI":"10.3390\/healthcare11070961"},{"key":"7193_CR80","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/art.23568","volume":"59","author":"PJ Healy","year":"2008","unstructured":"Healy PJ, Helliwell PS (2008) Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum 59:686\u2013691","journal-title":"Arthritis Rheum"},{"key":"7193_CR81","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1093\/rheumatology\/keg072","volume":"42","author":"JS Smolen","year":"2003","unstructured":"Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G et al (2003) A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 42:244\u2013257","journal-title":"Rheumatology (Oxford)"},{"key":"7193_CR82","first-page":"S75","volume":"30","author":"DC Sandoval","year":"2023","unstructured":"Sandoval DC, Fern\u00e1ndez-\u00c1vila DG (2023) Assessment tools in psoriatic arthritis: a review. Rev Colomb Reumatol 30:S75\u2013S86","journal-title":"Rev Colomb Reumatol"},{"key":"7193_CR83","doi-asserted-by":"publisher","first-page":"631","DOI":"10.2147\/TCRM.S101619","volume":"12","author":"F Salaffi","year":"2016","unstructured":"Salaffi F, Di Carlo M, Carotti M, Farah S, Gutierrez M (2016) The psoriatic arthritis impact of disease 12-item questionnaire: equivalence, reliability, validity, and feasibility of the touch-screen administration versus the paperand- pencil version. Ther Clin Risk Manag 12:631\u2013642","journal-title":"Ther Clin Risk Manag"},{"key":"7193_CR84","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00393-020-00830-2","volume":"80","author":"S Beider","year":"2021","unstructured":"Beider S, Flohr S, Gehlert S, Witte T, Ernst D (2021) Association of physical activity with fatigue and functional capacity in patients with rheumatoid arthritis. Z Rheumatol 80:113\u2013121","journal-title":"Z Rheumatol"},{"key":"7193_CR85","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett S, Jenkinson T, Kennedy L, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index. J Rheumatol 21:2286\u20132291","journal-title":"J Rheumatol"},{"key":"7193_CR86","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/j.0022-202X.2005.23621.x","volume":"125","author":"Y Hongbo","year":"2005","unstructured":"Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY (2005) Translating the science of quality of life into practice: What do dermatology life quality index scores mean? J Invest Dermatol 125:659\u2013664","journal-title":"J Invest Dermatol"},{"key":"7193_CR87","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","volume":"80","author":"F Alinaghi","year":"2019","unstructured":"Alinaghi F, Calov M, Kristensen LE, Gladman DD, Coates LC (2019) Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol 80:251\u2013265. https:\/\/doi.org\/10.1016\/j.jaad.2018.06.027","journal-title":"J Am Acad Dermatol"},{"key":"7193_CR88","doi-asserted-by":"publisher","unstructured":"Karmacharya CB, Crowson CS, Bekele D, Achenbach SJ, Davis Jr JC (2021) The epidemiology of psoriatic arthritis over five decades: a population-based study. Arthritis Rheumatol 73. https:\/\/doi.org\/10.1002\/art.41741","DOI":"10.1002\/art.41741"},{"key":"7193_CR89","unstructured":"National Psoriasis Foundation (2023) About Psoriatic Arthritis [updated 16 February 2024; cited 1 January 2024]. Available from: https:\/\/www.psoriasis.org\/about-psoriatic-arthritis\/. Accessed 1 Jan 2024"},{"key":"7193_CR90","doi-asserted-by":"publisher","first-page":"1759720X2110140","DOI":"10.1177\/1759720x211014010","volume":"13","author":"C Magee","year":"2021","unstructured":"Magee C, Jethwa H, Fitzgerald OM, Jadon DR (2021) Biomarkers predictive of treatment response in psoriasis and psoriatic arthritis: a systematic review. Ther Adv Musculoskelet Dis 13:1759720X2110140. https:\/\/doi.org\/10.1177\/1759720x211014010","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"7193_CR91","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1080\/17512433.2020.1758556","volume":"13","author":"C Mekhail","year":"2020","unstructured":"Mekhail C, Chouk M, Prati C, Wendling D, Verhoeven F (2020) Prognostic factors of good response to DMARDs in psoriatic arthritis: a narrative review. Expert Rev Clin Pharmacol 13:505\u2013519. https:\/\/doi.org\/10.1080\/17512433.2020.1758556","journal-title":"Expert Rev Clin Pharmacol"},{"key":"7193_CR92","doi-asserted-by":"publisher","unstructured":"Houttekiet C, de Vlam K, Neerinckx B, Lories R (2022) Systematic review of the use of CRP in clinical trials for psoriatic arthritis: a concern for clinical practice? RMD Open 8. https:\/\/doi.org\/10.1136\/rmdopen-2021-001756","DOI":"10.1136\/rmdopen-2021-001756"},{"key":"7193_CR93","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1002\/art.40921","volume":"71","author":"S Siebert","year":"2019","unstructured":"Siebert S, Sweet K, Dasgupta B, Campbell K, McInnes IB, Loza MJ (2019) Responsiveness of serum C-Reactive protein, Interleukin-17A, and Interleukin-17F levels to Ustekinumab in Psoriatic Arthritis: lessons from two phase III, multicenter, double-blind, placebo-controlled trials. Arthritis Rheumatol 71:1660\u20131669. https:\/\/doi.org\/10.1002\/art.40921","journal-title":"Arthritis Rheumatol"},{"issue":"317\u201321","key":"7193_CR94","first-page":"29094869","volume":"115","author":"C Bray","year":"2016","unstructured":"Bray C, Bell LN, Liang H, Haykal R, Kaiksow F, Mazza JJ et al (2016) Erythrocyte sedimentation rate and C-reactive protein measurements and their relevance in clinical medicine. WMJ 115(317\u201321):29094869","journal-title":"WMJ"},{"key":"7193_CR95","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1093\/rheumatology\/kew326","volume":"55","author":"P Hojgaard","year":"2016","unstructured":"Hojgaard P, Glintborg B, Kristensen LE, Gudbjornsson B, Love TJ, Dreyer L (2016) The influence of obesity on response to tumour necrosis factor-alpha inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries. Rheumatology (Oxford) 55:2191\u20132199. https:\/\/doi.org\/10.1093\/rheumatology\/kew326","journal-title":"Rheumatology (Oxford)"},{"key":"7193_CR96","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3899\/jrheum.171034","volume":"46","author":"A Ogdie","year":"2019","unstructured":"Ogdie A, Palmer JL, Greenberg J, Curtis JR, Harrold LR, Solomon DH et al (2019) Predictors of achieving remission among patients with psoriatic arthritis initiating a tumor necrosis factor inhibitor. J Rheumatol 46:475\u2013482. https:\/\/doi.org\/10.3899\/jrheum.171034","journal-title":"J Rheumatol"},{"key":"7193_CR97","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13075-021-02680-y","volume":"24","author":"E Passia","year":"2022","unstructured":"Passia E, Vis M, Coates LC, Soni A, Tchetverikov I, Gerards AH et al (2022) Sex-specific differences and how to handle them in early psoriatic arthritis. Arthritis Res Ther 24:22. https:\/\/doi.org\/10.1186\/s13075-021-02680-y","journal-title":"Arthritis Res Ther"},{"key":"7193_CR98","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s42358-023-00295-2","volume":"63","author":"F Molica Colella","year":"2023","unstructured":"Molica Colella F, Zizzo G, Parrino V, Filosa MT, Cavaliere R, Fazio F et al (2023) Effectiveness and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a 52-week real-life study in an Italian cohort. Adv Rheumatol 63:15. https:\/\/doi.org\/10.1186\/s42358-023-00295-2","journal-title":"Adv Rheumatol"},{"key":"7193_CR99","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1093\/rheumatology\/kez505","volume":"59","author":"F Iannone","year":"2020","unstructured":"Iannone F, Nivuori M, Fornaro M, Venerito V, Cacciapaglia F, Lopalco G (2020) Comorbid fibromyalgia impairs the effectiveness of biologic drugs in patients with psoriatic arthritis. Rheumatology (Oxford) 59:1599\u20131606. https:\/\/doi.org\/10.1093\/rheumatology\/kez505","journal-title":"Rheumatology (Oxford)"},{"key":"7193_CR100","doi-asserted-by":"publisher","first-page":"e010650","DOI":"10.1136\/bmjopen-2015-010650","volume":"6","author":"P Hojgaard","year":"2016","unstructured":"Hojgaard P, Christensen R, Dreyer L, Mease P, de Wit M, Skov L et al (2016) Pain mechanisms and ultrasonic inflammatory activity as prognostic factors in patients with psoriatic arthritis: protocol for a prospective, exploratory cohort study. BMJ Open 6:e010650. https:\/\/doi.org\/10.1136\/bmjopen-2015-010650","journal-title":"BMJ Open"},{"key":"7193_CR101","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s40744-018-0120-8","volume":"5","author":"K de Vlam","year":"2018","unstructured":"de Vlam K, Merola JF, Birt JA, Sandoval DM, Lobosco S, Moon R et al (2018) Skin involvement in psoriatic arthritis worsens overall disease activity, patient-reported outcomes, and increases healthcare resource utilization: an observational, cross-sectional study. Rheumatol Ther 5:423\u2013436. https:\/\/doi.org\/10.1007\/s40744-018-0120-8","journal-title":"Rheumatol Ther"},{"key":"7193_CR102","doi-asserted-by":"publisher","unstructured":"Cardner M, Tuckwell D, Kostikova A, Forrer P, Siegel RM, Marti A, et al (2023) Analysis of serum proteomics data identifies a quantitative association between beta-defensin 2 at baseline and clinical response to IL-17 blockade in psoriatic arthritis. RMD Open 9. https:\/\/doi.org\/10.1136\/rmdopen-2023-003042","DOI":"10.1136\/rmdopen-2023-003042"},{"key":"7193_CR103","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3899\/jrheum.180141","volume":"94","author":"DR Jadon","year":"2018","unstructured":"Jadon DR, Chandran V, Stober C, Ogdie A, Armstrong AW, Callis Duffin K et al (2018) Proceedings of the 2017 GRAPPA collaborative research network meeting. J Rheumatol Suppl 94:54\u201361. https:\/\/doi.org\/10.3899\/jrheum.180141","journal-title":"J Rheumatol Suppl"},{"key":"7193_CR104","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41746-023-00757-3","volume":"6","author":"J Xu","year":"2023","unstructured":"Xu J, Ou J, Li C, Zhu Z, Li J, Zhang H et al (2023) Multi-modality data-driven analysis of diagnosis and treatment of psoriatic arthritis. NPJ Digit Med 6:13. https:\/\/doi.org\/10.1038\/s41746-023-00757-3","journal-title":"NPJ Digit Med"},{"key":"7193_CR105","doi-asserted-by":"publisher","first-page":"152213","DOI":"10.1016\/j.semarthrit.2023.152213","volume":"61","author":"A Madrid-Garcia","year":"2023","unstructured":"Madrid-Garcia A, Merino-Barbancho B, Rodriguez-Gonzalez A, Fernandez-Gutierrez B, Rodriguez-Rodriguez L, Menasalvas-Ruiz E (2023) Understanding the role and adoption of artificial intelligence techniques in rheumatology research: an in-depth review of the literature. Semin Arthritis Rheum 61:152213. https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152213","journal-title":"Semin Arthritis Rheum"},{"key":"7193_CR106","doi-asserted-by":"publisher","first-page":"100207","DOI":"10.1016\/j.jtauto.2023.100207","volume":"7","author":"J Shapiro","year":"2023","unstructured":"Shapiro J, Getz B, Cohen SB, Jenudi Y, Underberger D, Dreyfuss M et al (2023) Evaluation of a machine learning tool for the early identification of patients with undiagnosed psoriatic arthritis - A retrospective population-based study. J Transl Autoimmun 7:100207. https:\/\/doi.org\/10.1016\/j.jtauto.2023.100207","journal-title":"J Transl Autoimmun"},{"key":"7193_CR107","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.semarthrit.2017.01.008","volume":"47","author":"F Iannone","year":"2017","unstructured":"Iannone F, Santo L, Anelli MG, Bucci R, Semeraro A, Quarta L et al (2017) Golimumab in real-life settings: 2 Years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Semin Arthritis Rheum 47:108\u2013114. https:\/\/doi.org\/10.1016\/j.semarthrit.2017.01.008","journal-title":"Semin Arthritis Rheum"},{"key":"7193_CR108","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1093\/rheumatology\/kead284","volume":"63","author":"L Linde","year":"2024","unstructured":"Linde L, Ornbjerg LM, Georgiadis S, Rasmussen S, Lindstrom U, Askling J et al (2024) Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor: results from 13 European registries. Rheumatology (Oxford) 63:751\u201364. https:\/\/doi.org\/10.1093\/rheumatology\/kead284","journal-title":"Rheumatology (Oxford)"},{"key":"7193_CR109","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1080\/03009742.2023.2258644","volume":"53","author":"C Roseman","year":"2024","unstructured":"Roseman C, Wallman JK, Joud A, Schelin M, Einarsson JT, Lindqvist E et al (2024) Persistent pain and its predictors after starting anti-tumour necrosis factor therapy in psoriatic arthritis: what is the role of inflammation control? Scand J Rheumatol 53:94\u2013103. https:\/\/doi.org\/10.1080\/03009742.2023.2258644","journal-title":"Scand J Rheumatol"},{"key":"7193_CR110","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1002\/jrsm.1452","volume":"11","author":"A Marks-Anglin","year":"2020","unstructured":"Marks-Anglin A, Chen Y (2020) A historical review of publication bias. Res Synth Methods 11:725\u201342. https:\/\/doi.org\/10.1002\/jrsm.1452","journal-title":"Res Synth Methods"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-07193-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-024-07193-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-07193-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T11:04:17Z","timestamp":1732187057000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-024-07193-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,28]]},"references-count":110,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["7193"],"URL":"https:\/\/doi.org\/10.1007\/s10067-024-07193-y","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,28]]},"assertion":[{"value":"11 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Authorisation from the ethics committee was not required for this study (BASEC-Nr. Req-2022\u201300563, Kantonale Ethikkommission, Kanton Z\u00fcrich, Switzerland).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"The authors declare that they do not have any financial relationships relevant to this article to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial disclosure"}},{"value":"The authors confirm that patients or the public were not involved in the planning, conduct, reporting or dissemination of this research.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient and public involvement"}},{"value":"The authors declare that they have no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Potential conflicts of interest"}}]}}